rivaroxaban + azathioprine + methylprednisolone

This combination regimen consists of the oral anticoagulant rivaroxaban and a standard immunosuppressive backbone of azathioprine and methylprednisolone. It is currently being evaluated in a Phase III clinical trial led by Marmara University for the treatment of lower extremity venous thrombosis in patients with Behçet's Disease. Rivaroxaban is a small molecule direct Factor Xa inhibitor that prevents blood clot formation by blocking a key enzyme in the coagulation cascade. Azathioprine is an immunosuppressive antimetabolite that inhibits purine synthesis, while methylprednisolone is a corticosteroid that exerts anti-inflammatory effects via the glucocorticoid receptor. The regimen aims to address both the thrombotic complications and the underlying systemic vasculitis associated with Behçet's Disease.

Brand names

XareltoImuranMedrol

Other names

Rivaroxaban plus immunosuppression